Brief Summary

This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT05455931?term=PROSPER&cond=Cutaneous%20Lymphomas&rank=1

Sponsor: Kyowa Kirin Pharmaceutical Development Ltd

Detailed Description

The PROSPER study aims to collect information about the experiences of patients with MF/SS receiving Poteligeo and of their caregivers in real-world clinical practice. The objective of this study is to generate patient-level data to provide insights into real world clinical practice and an understanding of treatment decisions, as well as to collect patient reported outcomes (PRO) data, enriched with qualitative data on disease and treatment experience and burden, to demonstrate the full impact of treatment and the relevant patient experience in real-world clinical practice. The study will be conducted in up to 8 countries, including North America and countries in Europe, at approximately 20 sites known to treat and follow-up patients with MF/SS. Patients will be followed for up to 50 weeks from study enrollment.

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05455931

Contact: Division Project Management Department 609-919-1100 Email: kkd.clintrial.82@kyowakirin.com